|  |
| --- |
| The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the PBS or the National Immunisation Program.The PBAC agenda consists of the following:**1 Minutes of Previous Meeting****2 Chairman’s report (verbal)****3 Matters arising from the minutes****4 Matters arising/outstanding****5 New drug applications****6 Requests for changes to listings****7 Resubmissions****8 Pricing Matters****9 Matters relating to PBS review****10 Subcommittee and Working Party reports****11 Other business****12 Correspondence****13 Further information****14 Late papers****15 Tabled papers**Consumers will have the opportunity to provide comments on new drug submissions (item 5), changes to listings (item 6) and resubmissions (item 7). In many circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceutical benefits listed in the Schedule fall into three broad categories:*Unrestricted benefits* – have no restrictions on their therapeutic uses; *Restricted benefits* – can only be prescribed for specific therapeutic uses (noted as Restricted benefit); and *Authority required benefits* – Authority required benefits fall into two categories: * *Authority required benefits* require prior approval from Medicare Australia or the DVA (noted as Authority required)
* *Authority required (STREAMLINED) benefits* do not require prior approval from Medicare Australia or the DVA but require the recording of a streamlined authority code (noted as Authority required (STREAMLINED)).

Submissions are categorised broadly as major or minor:* *Major:* Submissions to list new medicines on the Schedule of Pharmaceutical Benefits or to make substantial changes to current listings are generally classified as major submissions. Major submissions require presentation of an economic evaluation.
* *Minor:* Submissions that relate to new forms of previously listed products and changes to the conditions of use e.g. change in maximum quantity/repeats or clarifying the wording of a restriction (while not altering the intended use) are considered to be minor submissions. Minor submissions do not usually require the presentation of an economic evaluation.
 |

| **Submission type**(new listing, change to listing) | **Drug Name, form(s), strength(s) and Sponsor**(Drug name, form, strength, Trade name®, Sponsor) | **Drug Type and Use**(What is the drug used to treat?) | **Listing requested by Sponsor / Purpose of Submission**(Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
| --- | --- | --- | --- |
| Change to listing(Major Submission) | ABATACEPTInjection 125 mg in 1 mL single dose autoinjectorInjection 125 mg in 1 mL single dose pre-filled syringePowder for I.V. infusion 250 mgOrencia®Orencia ClickJect®Bristol-Myers Squibb Australia Pty Ltd | Psoriatic arthritis (PsA) | To request an Authority Required listing for the treatment of patients with severe active PsA. |
| Change to recommended listing(Minor Submission) | ADRENALINEI.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injectorI.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injectorAdrenaJect®Sun Pharma ANZ Pty Ltd  | Anaphylaxis | To request that the PBAC reconsider its previous recommendation that AdrenaJect not be considered equivalent for the purposes of substitution with the reference originator.  |
| Change to listing(Minor Submission) | 1) AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE2) AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE AND TYROSINE3) AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT METHIONINEOral liquid 87 mL, 30;Oral liquid 130 mL, 30; andOral liquid 174 mL, 301) MSUD cooler 10, 15 and 20;2) TYR cooler 10, 15 and 20; and3) HCU cooler 10, 15 and 20Vitaflo Australia Pty Ltd | 1)Maple Syrup Urine Disease (MSUD)2)Tyrosinaemia (TYR)3)Homocystinuria (HCU) | To request changes to the Restricted Benefit listings of MSUD, TYR and HCU Coolers including nutritional content. |
| New listing(Minor Submission) | AMINO ACID FORMULA WITH VITAMINS, MINERALS AND LONG CHAIN POLYUNSATURATED FATTY ACIDS, WITHOUT PHENYLALANINEOral powder 400 g (PKU Start)PKU Start®Vitaflo Australia Pty Ltd | Phenylketonuria | To request a Restricted Benefit listing for the dietary management of patients with phenylketonuria. |
| New listing(Minor Submission) | APOMORPHINESolution for subcutaneous infusion containing apomorphine hydrochloride 30 mg in 3 mL pre-filled penMovapo PenStada Pharmaceuticals Australia Pty Ltd | Parkinson disease | To request a Section 100 (Highly Specialised Drugs Program - Public and Private Hospital) listing of a new form of apomorphine. |
| New listing(Minor Submission) | APREMILAST Tablet 30 mgPack containing 4 tablets of 10 mg , 4 tablets of 20 mg and 19 tablets of 30 mgOtezla®Celgene Pty Ltd | Moderate to severe plaque psoriasis | Resubmission to request an Authority Required (STREAMLINED) listing for the treatment of patients with moderate to severe plaque psoriasis. |
| New listing(Minor Submission) | ARGININETablet 500 mgArginine Easy®Orpharma Pty Ltd | Urea cycle disorders (UCD) | To request a Restricted Benefit listing for the treatment of UCD. |
| New listing(Major Submission) | ASFOTASE ALFAInjection 18 mg in 0.45 mL vialInjection 28 mg in 0.7 mL vialInjection 40 mg in 1 mL vialInjection 80 mg in 0.8 mL vialStrensiq®Alexion Pharmaceuticals Australasia Pty Ltd | Hypophosphatasia (HPP) | Resubmission to request a Section 100 (Highly Specialised Drugs Program) listing for the treatment of patients with juvenille onset HPP who meet certain conditions. |
| New listing(Major Submission) | BENRALIZUMAB30mg in 1 mL solution for injection prefilled syringeFasenra® AstraZeneca Pty Ltd | Uncontrolled severe eosinophilic asthma | To request a Section 100 (Highly Specialised Drug Program) Authority Required listing for the treatment of uncontrolled severe eosinophilic asthma in patients aged 18 years and over. |
| Change to listing (Minor Submission) | BENRALIZUMAB30mg in 1 mL solution for injection prefilled syringeFasenra® AstraZeneca Pty Ltd | Uncontrolled severe eosinophilic asthma | To request amendments to the current Section 100 (Highly Specialised Drugs Program - Public and Private Hospital) restrictions for uncontrolled severe eosinophilic asthma. |
| Change to recommended listing(Major Submission) | BOTULINUM TOXIN TYPE A PURIFIED NEUROTOXIN COMPLEXLyophilised powder for injection 100 unitsBotox® Allergan Australia Pty Limited | Chronic migraine | To request a revision to the existing risk sharing arrangements. |
| Change to listing(Minor Submission) | CALCIPOTRIOL with BETAMETHASONEGel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 gDaivobet 50/500® GelLeo Pharma Pty Ltd | Chronic stable plaque type psoriasis vulgaris | To request additional Authority Required (STREAMLINED) listings with increased maximum quantities based on percentage of Body Surface Area (BSA) to be treated. |
| Change to listing(Major Submission) | CETUXIMABSolution for I.V. infusion 100 mg in 20 mLSolution for I.V. infusion 500 mg in 100 mLErbitux®Merck Serono Australia Pty Ltd | Recurrent or metastatic squamous cell carcinoma of the head and neck  | To request a Section 100 (Efficient Funding of Chemotherapy) Authority Required listing for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck. |
| New listing(Minor Submission) | CLADRIBINETablet 10 mgMavenclad®Merck Serono Australia Pty Ltd | Relapsing-remitting multiple sclerosis (RRMS) | Resubmission to request an Authority Required listing for the treatment of RRMS. |
| Change to listing(Major Submission) | DEXAMETHASONEIntravitreal injection 700 microgramsOzurdex®Allergan Australia Pty Ltd | Macular oedema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). | To request an Authority Required listing for the treatment of macular oedema secondary to BRVO and CRVO. |
| Change to recommended listing (Minor Submission) | ECULIZUMABSolution concentrate for I.V. infusion 300 mg in 30 mLSoliris®Alexion Pharmaceuticals Australasia Pty Limited | Atypical haemolytic uraemic syndrome (aHUS) in end stage renal disease (ESRD)  | To request an extension in the recommended eculizumab treatment duration for patients with aHUS in ESRD who are eligible for a renal transplant. |
| New listing(Major Submission) | 1) ERTUGLIFLOZIN2) ERTUGLIFLOZIN WITH METFORMIN1) Tablet containing 5 mg ertugliflozin;Tablet containing 15 mg ertugliflozin2) Tablet containing 2.5 mg ertugliflozin with 500 mg metformin hydrochloride;Tablet containing 2.5 mg ertugliflozin with 1 g metformin hydrochloride;Tablet containing 7.5 mg ertugliflozin with 500 mg metformin hydrochloride;Tablet containing 7.5 mg ertugliflozin with 1 g metformin hydrochloride;1) Steglatro® (TBC)2) Segluromet® (TBC)Merck Sharp & Dohme (Australia) Pty Limited  | Type 2 diabetes mellitus (T2DM) | To request an Authority Required (STREAMLINED) listing for dual oral combination therapy for patients with T2DM who are inadequately controlled with metformin or a sulfonylurea. |
| New listing(Minor Submission) | ETANERCEPTInjection 50 mg in 1 mL single use auto-injector, 4Injection 50 mg in 1 mL single use pre-filled syringes, 4Erelzi®Sandoz Pty Ltd | Rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis (JIA), paediatric plaque psoriasis | To request an Authority Required listing for the same indications as the reference biologic. |
| Change to listing(Minor Submission) | EVOLOCUMABInjection 420 mg in 3.5 mL single use pre-filled cartridgeInjection 140 mg in 1 mL single use pre-filled penRepatha® Amgen Australia Pty Limited | Familial hypercholesterolaemia (FH) | Resubmission to request an Authority Required listing for treatment of patients with FH who have either very high LDL-c or symptomatic atherosclerotic cardiovascular disease (ASCVD).  |
| Change to listing (Minor Submission) | FILGRASTIMInjection 120 micrograms in 0.2 mL single use pre-filled syringe (Nivestim)Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)Nivestim® Pfizer Australia Pty Ltd | Chemotherapy-induced neutropenia;Mobilisation of peripheral blood progenitor cells;Assisting bone marrow transplantation;Assisting autologous peripheral blood progenitor cell transplantation;Severe congenital neutropenia;Severe chronic neutropenia;Chronic cyclical neutropenia | To request that the current listings of Nivestim be changed to Authority Required (STREAMLINED) for Section 100 Highly Specialised Drugs (Private Hospital). |
| Change to listing(Minor Submission) | FOLLITROPIN ALFAInjection 75 I.U. in 0.125 mL pre-filled penInjection 150 I.U. in 0.25 mL pre-filled penInjection 225 I.U. in 0.375 mL pre-filled penInjection 300 I.U. in 0.5 mL pre-filled penInjection 450 I.U. in 0.75 mL pre-filled penBemfola®Gedeon Richter Australia Pty Ltd | Assisted Reproductive Technology (ART);Anovulatory infertility;Infertility due to hypogonadotrophic hypogonadism | To request that the current listings of Bemfola be changed to a Restricted Benefit (for the Section 100 IVF listings), and to include a NOTE encouraging prescribing for treatment-naïve patients. |
| Change to listing(Minor Submission) | GRAZOPREVIR + ELBASVIRTablet containing grazoprevir 100 mg with elbasvir 50 mgZepatierTMMerck, Sharp and Dohme Australia Pty Limited | Chronic Hepatitis C virus infection | To request that the current General Schedule and Section 100 (Highly Specialised Drug) listings be changed to Authority Required (STREAMLINED) and amendments to the General Statement for Drugs for the treatment of Hepatitis C to allow for this change. |
| New listing(Major Submission) | GUSELKUMABInjection 100 mg in 1 mL single use pre-filled syringe Tremfya®Janssen-Cilag Pty Ltd | Severe chronic plaque psoriasis | To request an Authority Required listing for the treatment of severe chronic plaque psoriasis.  |
| New listing(Minor Submission) | HYDROMORPHONEOral liquid containing hydromorphone hydrochloride 1 mg per mL, 200 mLDilaudid®Mundipharma Pty Ltd | Severe disabling pain | To request a Restricted Benefit listing for the treatment of severe disabling pain. |
| Change to listing(Minor Submission) | IBRUTINIBCapsule 140 mg Imbruvica®Janssen-Cilag Pty Ltd | Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) and relapsed or refractory mantle cell lymphoma (MCL) | Resubmission to request an Authority Required listing for the first line treatment of patients with CLL or SLL who meet certain criteria and relapsed or refractory MCL. |
| New listing(Minor Submission) | INSULIN DEGLUDEC WITH INSULIN ASPARTInjections, cartridges, 70 units-30 units per mL, 3 mL, 5Injections, pre-filled pen, 70 units-30 units per mL, 3 mL, 5Ryzodeg FlexTouch®Ryzodeg Penfill®Novo Nordisk Pharmaceuticals Pty Ltd | Diabetes mellitus | Resubmission to request an unrestricted listing to improve glycaemic control in adult patients with diabetes mellitus where basal and prandial insulin treatment is necessary. |
| New listing(Major Submission) | INSULIN GLARGINE WITH LIXISENATIDEInjections (human analogue), cartridges, insulin glargine 100 units per mL with lixisenatide 50 microgram per mL, 3 mL, 5Injections (human analogue), cartridges, insulin glargine 100 units per mL with lixisenatide 33 microgram per mL, 3 mL, 5Soliqua®Sanofi-aventis Australia Pty Ltd | Type 2 diabetes mellitus (T2DM) | To request an Authority Required (STREAMLINED) listing for the treatment of patients with T2DM who have inadequate glycaemic control with basal insulin. |
| New listing(Major Submission) | IRINOTECAN (NANOLIPOSOMAL)Injection concentrate for I.V. infusion 43 mg (as sucrosofate) in 10 mLOnivyde®Shire Australia Pty Ltd | Metastatic pancreatic cancer | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for the treatment of metastatic pancreatic cancer in combination with 5-fluorouracil and folinic acid (5-FU/LV) in patients who have progressed following treatment with a gemcitabine based regimen. |
| Change to listing(Major Submission) | LENALIDOMIDECapsule 5 mgCapsule 10 mgCapsule 15 mgRevlimid® Celgene Pty Ltd | Multiple myeloma | To request extension to the Section 100 (Highly Specialised Drug Program) Authority Required listing to include maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone an autologous stem cell transplant.  |
| Change to recommended listing (Minor Submission) | LENVATINIB Capsule 10 mg (as mesilate)Capsule 4 mg (as mesilate)Lenvima®Eisai Australia Pty Ltd | Advanced renal cell carcinoma | Resubmission to request an Authority Required (STREAMLINED) listing for the treatment of patients with advanced renal cell carcinoma following treatment with at least one anti-angiogenic therapy. |
| Change to recommended listing (Minor Submission) | LIRAGLUTIDEInjection 6 mg/mL, 3mL pre-filled penVictoza®Novo Nordisk Pharmaceuticals Pty Limited | Type 2 diabetes mellitus (T2DM) | To request an amendment to the recommended listing to include a Special Pricing Arrangement. |
| New listing(Major Submission) | MENINGOCOCCAL POLYSACCHARIDE SEROGROUPS A, C, W-135 AND Y CONJUGATE VACCINEInjection 0.5 mL in pre-filled syringeNimenrix®Pfizer Australia Pty Ltd | Meningococcal disease | To request listing on the National Immunisation Program (NIP) for the active immunisation of infants. |
| New listing(Major Submission) | MENINGOCOCCAL POLYSACCHARIDE SEROGROUPS A, C, W-135 AND Y CONJUGATE VACCINEInjection 0.5 mL in pre-filled syringeNimenrix®Pfizer Australia Pty Ltd | Meningococcal disease | To request listing on the National Immunisation Program (NIP) for the immunisation of adolescents in Year 10 and a catch-up program for adolescents aged up to 19 years administered via a school or GP-based catch up program. |
| Change to listing(Minor Submission) | MEPOLIZUMABPowder for injection 100 mgNucala®GlaxoSmithKline Australia Pty Ltd | Severe eosinophilic asthma | To request changes to the current Section 100 (Highly Specialised Drugs Program) Authority Required listing by removing the 6 month waiting period between the reuse of, or switching between omalizumab and mepolizumab. |
| New listing(Minor Submission) | NANDROLONE DECANOATEInjection 50 mg in 1 mL ampouleDeca-Durabolin®Aspen Pharmacare Australia Pty Ltd | Osteoporosis | To request an Authority Required listing of a new form of nandrolone decanoate for the treatment of osteoporosis. |
| New listing(Other Submission) | NICOTINEGum 2 mgGum 4 mgLozenge 2 mgLozenge 4 mgNicotinell Chewing gum®Nicotinell lozenge®Orion Laboratories Pty Ltd T/A Perrigo Australia | Nicotine dependence | To request a Restricted Benefit listing for nicotine chewing gum and lozenges to aid smoking cessation in patients with nicotine dependence. |
| Change to listing(Minor Submission) | NIVOLUMABInjection concentrate for I.V. infusion 40 mg in 4 mLInjection concentrate for I.V. infusion 100 mg in 10 mLOpdivo®Bristol-Myers Squibb Australia Pty Ltd | Squamous cell carcinoma for the head and neck (SCCHN) | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for the treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) who progress within 6 months following platinum-based therapy. |
| New listing(Minor Submission) | NUSINERSENSolution for injection 12 mg in 5 mLSpinraza™Biogen Australia Pty Ltd | Treatment of infantile-onset (Type I) spinal muscular atrophy (SMA) | To request a Section 100 (Highly Specialised Drugs Program) Authority Required listing for the treatment of Type I SMA. |
| Change to listing(Minor Submission) | OBINUTUZUMAB Solution for I.V. infusion 1000 mg in 40 mLGazyva®Roche Products Pty Ltd  | CD20 positive follicular lymphoma | Resubmission to request an Authority Required (STREAMLINED) listing for untreated patients with Stage II bulky or Stage III/IV CD20 positive follicular lymphoma or rituximab-refractory follicular lymphoma. |
| New listing(Major Submission) | OLAPARIBTablet 100 mgTablet 150 mgLynparza®AstraZeneca Pty Ltd | High-grade serous ovarian, fallopian tube and primary peritoneal cancer | To request an Authority Required listing for the treatment of high-grade serious ovarian, fallopian tube and primary peritoneal cancer. |
| Change to listing (Minor Submission) | OMALIZUMABInjection 150 mg in 1 mL single dose pre-filled syringeXolair®Novartis Pharmaceuticals Australia Pty Ltd  | Severe chronic spontaneous urticaria | To request a General Schedule Authority Required listing for the treatment of severe chronic spontaneous urticaria in addition to the current Section 100 (Highly Specialised Drug) listing.  |
| New listing(Minor Submission) | PALBOCICLIBCapsule 75 mgCapsule 100 mg Capsule 125 mgIbrance®Pfizer Australia Pty Ltd | Hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer | Resubmission to request an Authority Required listing as initial endocrine-based therapy in patients with HR+, HER2- locally advanced, inoperable or metastatic breast cancer in combination with a non-steroidal aromatase inhibitor. |
| Change to listing(Minor Submission) | PEMBROLIZUMABPowder for injection 50 mg Solution concentrate for I.V. infusion 100 mg in 4 mLKeytruda®Merck, Sharp & Dohme (Australia) Pty Ltd | First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing as first line monotherapy in patients expressing PD-L1 for NSCLC. |
| Change to listing(Minor Submission) | PEMBROLIZUMABPowder for injection 50 mgSolution concentrate for I.V. infusion 100 mg in 4 mLKeytruda®Merck, Sharp and Dohme (Australia) Pty Limited | Melanoma | To request a change to the dosing regimen to a fixed dose, from weight-based dosing, with a new maximum amount. |
| New listing (Minor Submission) | PERFLUOROHEXYLOCTANEEye drops containing perfluorohexyloctane, 3 mLNovaTears® AFT Pharmaceuticals Pty Ltd | Severe dry eye syndrome | To request an Authority Required (STREAMLINED) listing for the treatment of severe dry eye syndrome. |
| New listing(Minor Submission) | PIRFENIDONETablet 267 mgTablet 801 mg Esbriet®Roche Products Pty Ltd  | Idiopathic pulmonary fibrosis | To request an Authority Required listing for two new forms of pirfenidone. |
| Change to listing(Minor Submission) | PNEUMOCOCCAL CONJUGATE VACCINE, 13 VALENTInjection 0.5 mLPrevenar 13®Pfizer Australia Pty Ltd | Prevention of pneumococcal disease | To request a change to the National Immunisation Program (NIP) infant schedule for 13-valent pneumococcal vaccine from a 3+0 to a 2+1 schedule. |
| Change to listing(Minor Submission) | PROTEIN HYDROLYSATE FORMULA WITH MEDIUM CHAIN TRIGLYCERIDESOral powder 450 g (Aptamil Gold+ Pepti-Junior)Aptamil Gold+ Pepti-Junior®Danone Nutricia | Cow's milk protein enteropathy and intolerance to soy protein;Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein and soy protein;Biliary atresia;Chronic liver failure with fat malabsorption;Chylous ascites;Cystic fibrosis;Enterokinase deficiency;Proven fat malabsorption;Severe diarrhoea of greater than 2 weeks duration;Severe intestinal malabsorption including short bowel syndrome | To request changes to the Authority Required (STREAMLINED) listing of Aptamil Gold+ Pepti-Junior including nutritional content. |
| New listing(Major Submission) | RAMUCIRUMABInjection concentrate for I.V. infusion 100 mg in 10 mLInjection concentrate for I.V. infusion 500 mg in 50 mLCyramza®Eli Lilly Australia Pty Ltd | Advanced gastric or gastro-oesophageal junction adenocarcinomas | To request a Section 100 (Efficient Funding of Chemotherapy) listing for the treatment of patients with advanced or metastatic, gastric or gastro-oesophageal junction adenocarcinoma in with disease progression, in combination with paclitaxel after prior platinum and fluoropyrimidine chemotherapy. |
| Change to listing(Major Submission) | RANIBIZUMABSolution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringeSolution for intravitreal injection 2.3 mg in 0.23 mLLucentis® Norvartis Pharmaceuticals Australia Pty Ltd | Visual impairment due choroidal neovascularisation (CNV)  | To request an Authority Required listing for the treatment of patients with rare choroidal neovascularisation CNV secondary to pathologic myopia. |
| Change to listing(Major Submission) | RANIBIZUMABSolution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringeSolution for intravitreal injection 2.3 mg in 0.23 mLLucentis® Norvartis Pharmaceuticals Australia Pty Ltd | Visual impairment due to choroidal neovascularisation (CNV) | To request an Authority Required listing for the treatment of patients with visual impairment due to rare CNV. |
| New Listing(Minor Submission) | RANOLAZINETablet (modified release) 375 mgTablet (modified release) 500 mgTablet (modified release) 750 mgRanexa®A. Menarini Australia Pty Ltd | Stable angina pectoris | Resubmission to request an Authority Required listing as an add-on therapy for the symptomatic treatment of stable angina pectoris. |
| New listing(Major Submission) | REGORAFENIBTablet 40 mg (as monohydrate)Stivarga®Bayer Australia Ltd | Hepatocellular carcinoma (HCC) | To request an Authority Required (STREAMLINED) listing for the treatment of patients with unresectable HCC who have progressed on sorafenib treatment. |
| New listing(Minor Submission) | RIBOCICLIBTablet 200 mgKisqali®Novartis Pharmaceuticals Australia Pty Ltd | Hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer | Resubmission to request an Authority Required listing as initial endocrine-based therapy in patients with HR+, HER2- locally advanced, inoperable or metastatic breast cancer in combination with a non-steroidal aromatase inhibitor, who are not premenopausal. |
| New listing(Minor Submission) | RITUXIMABSolution for I.V. infusion 100 mg in 10 mLSolution for I.V. infusion 500 mg in 50 mLRiximyo®Sandoz Pty Ltd | CD20 positive follicular B-cell non-Hodgkin's lymphoma;Severe active granulomatosis with polyangiitis (Wegeners granulomatosis);CD20 positive non-Hodgkin's lymphoma;Low-grade B-cell non-Hodgkin's lymphoma;Chronic lymphocytic leukaemia;Severe active rheumatoid arthritis  | To request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) and Section 100 Authority Required (Highly Specialised Drug) listings for the same indications as the reference biologic.  |
| Change to listing(Major Submission) | SAPROPTERINTablet (soluble) containing sapropterin dihydrochloride 100 mgKuvan®BioMarin Pharmaceutical Australia Pty Ltd | Hyperphenylalaninemia (HPA) | To request an Authority Required listing for the treatment of HPA in patients with phenylketonuria. |
| New listing(Minor Submission) | SODIUM PHENYLBUTYRATEGranules 483 mg (as sodium) per g, 174 gPheburane®Orpharma Pty Ltd | Urea cycle disorder (UCD) | Resubmission to request an Authority Required listing for the treatment of patients with UCD. |
| New listing(Major Submission) | SOFOSBUVIR WITH VELPATASVIR WITH VOXILAPREVIRTablet containing sofosbuvir 400 mg with velpatasvir 100 mg and voxilaprevir 100 mgVosevi®Gilead Sciences Pty Ltd | Chronic hepatitis C virus (HCV) infection | To request a General Schedule and Section 100 (Highly Specialised Drugs Program) listing for the treatment of HCV infection in adults who have failed treatment with an NS5A-based direct acting antiviral treatment regimen, regardless of genotype. |
| New listing(Major Submission)WITHDRAWN | STIRIPENTOLCapsule 250 mgCapsule 500 mgPowder for oral suspension 250 mgPowder for oral suspension 500 mgDiacomit®Emerge Health Pty Ltd | Severe myoclonic epilepsy in infancy (SMEI) | To request an Authority Required (STREAMLINED) listing for treatment in combination with sodium valproate and clobazam as adjunctive treatment of generalised tonic-clonic and clonic seizures in patients with SMEI (Dravet Syndrome) whose seizures are not adequately controlled with sodium valproate and clobazam. |
| New listing(Major Submission) | TENOFOVIR ALAFENAMIDE WITH EMTRICITABINE AND BICTEGRAVIRTablet containing tenofovir alafenamide 25 mg with emtricitabine 200 mg and bictegravir 50 mgTrade name to be determinedGilead Sciences Pty Ltd | Human immunodeficiency virus (HIV) infection | To request a Section 100 (Highly Specialised Drugs Program - Community Access) Authority Required (STREAMLINED) listing for the treatment of patients with HIV infection. |
| Change to listing(Major Submission) | TIOTROPIUMSolution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations)Spiriva Respimat®Boehringer Ingelheim Pty Ltd | Severe asthma | To request an Authority Required (STREAMLINED) listing for the treatment of severe asthma in children aged 6 years or older. |
| New listing(Major Submission) | TOLVAPTANPack containing 28 tablets 15 mg and 28 tablets 45 mgPack containing 28 tablets 30 mg and 28 tablets 60 mgPack containing 28 tablets 30 mg and 28 tablets 90 mgJinarc®Otsuka Australia Pharmaceutical Pty Ltd | Autosomal dominant polycystic kidney disease (ADPKD) | Resubmission to request an Authority Required listing for the treatment of ADPKD. |
| New listing(Major Submission) | TRAMADOL HYDROCHLORIDE WITH PARACETAMOLTablet containing tramadol hydrochloride 37.5 mg with paracetamol 325 mgZaldiar®Aspen Pharmacare Australia Pty Ltd | Acute and chronic pain  | To request a Restricted Benefit listing for the treatment of acute and chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed. |
| New listing(Minor Submission) | TRIFLURIDINE WITH TIPIRACILTablet containing 15 mg trifluridine with 6.14 mg tipiracil (as hydrochloride)Tablet containing 20 mg trifluridine with 8.19 mg tipiracil (as hydrochloride)Lonsurf®Servier Laboratories (Australia) Pty Ltd | Metastatic colorectal cancer | Resubmission to request an Authority Required (STREAMLINED) listing for the treatment of metastatic colorectal cancer. |
| Change to listing (Minor Submission) | TRIGLYCERIDES, LONG CHAIN WITH GLUCOSE POLYMER Oral liquid 250 mL, 18 (ProZero)Oral liquid 1 L, 6 (ProZero)ProZeroVitaflo Australia Pty Ltd | Proven inborn errors of protein metabolism | To request changes to the Restricted Benefit listing of ProZero including nutritional content. |
| New listing(Minor Submission) | TRIVALENT INFLUENZA VACCINE (High dose)Injection 0.5 mLFluzone® High-DoseSanofi-aventis Australia Pty Ltd | Prevention of seasonal influenza | To request National Immunisation Program (NIP) listing for the prevention of seasonal influenza in patients aged 65 years and over.  |
| New listing(Minor Submission) | TRIVALENT INFLUENZA VACCINEInjection 0.5 mLFluad® Seqirus (Australia) Pty Ltd | Prevention of seasonal influenza | To request National Immunisation Program (NIP) listing for the prevention of seasonal influenza in patients aged 65 years and over.  |
| Matters relating to PBS Review(DUSC Analysis) | Fluconazole(Diflucan®, Pfizer Australia Pty Ltd); (Dizole®, Fluconazole Alphapharm®, Alphapharm Pty Ltd);(Fluconazole-Sandoz®, Sandoz Pty Ltd);(Ozole®, Sun Pharma ANZ Pty Ltd);(APO-fluconazole®, Apotex Pty Ltd);(Fluzole®, Arrow Pharma Pty Ltd)Itraconazole(Lozanoc®, Mayne Pharma International Pty Ltd);(Sporanox®, Janssen-Cilag Pty Ltd);(APO-itraconazole®, Apotex Pty Ltd);(Itranox®, Arrow Pharma Pty Ltd); (Itracap®, Alphapharm Pty Ltd); | Antifungals | To consider options to address the increasing use of PBS subsidised fluconazole and itraconazole after they changed from Authority Required (STREAMLINED) to Restricted Benefit listings. |
| Matters relating to PBS Review(DUSC Analysis) | Prescriber bag medicines | Drugs used for emergencies | To review currently listed drugs and consider requests to add new drugs and prescriber types. |
| Sub-committee report(DUSC Analysis) | Bevacizumab (Avastin®, Roche Products Pty Ltd);Cetuximab (Erbitux®, Merck Serono Australia Pty Ltd);Panitumumab (Vectibix®, Amgen Australia Pty Limited) | Metastatic colorectal cancer | To assess the utilisation of targeted therapies for metastatic colorectal cancer; including PBS listed bevacizumab, cetuximab and panitumumab.  |
| Sub-committee report(DUSC Analysis) | Trastuzumab (Herceptin®, Herceptin® SC, Roche Products Pty Ltd);Trastuzumab emtansine (Kadcyla®, Roche Products Pty Ltd);Pertuzumab (Perjeta®, Roche Products Pty Ltd) | HER2 positive metastatic breast cancer | To compare the predicted and actual utilisation of trastuzumab, trastuzumab emtansine and pertuzumab for HER2 positive metastatic breast cancer. |
| Sub-committee report(DUSC Analysis) | Ivacaftor (Kalydeco®, Vertex Pharmaceuticals (Australia) Pty Ltd) | Cystic fibrosis | To report on the predicted versus actual use of ivacaftor in the treatment of cystic fibrosis.  |
| Matters relating to PBS Review(Evaluation of Post market review) | OmeprazolePantoprazole LansoprazoleRabeprazoleEsomeprazoleEsomeprazole, clarithromycin & amoxicillinOmeprazole, amoxicillin & clarithromycin (delisted in 2014)(all current and previously listed brands including generic versions) | Gastro-oesophageal reflux disorders | To consider a drug utilisation review of use of PBS listed Proton Pump Inhibitor medicines and review DUSC’s consideration of the findings. |
| Matters relating to PBS Review(Evaluation of Post market review) | SalbutamolTerbutaline Ipratropium Beclomethasone Fluticasone Budesonide Ciclesonide Sodium cromoglycate Nedocromil sodium Montelukast Salmeterol Eformoterol Fluticasone with SalmeterolFluticasone with Eformoterol Fluticasone with Vilanterol Budesonide with Eformoterol Oral glucocorticoids, plain(all listed brands) | Asthma | To consider the findings from the evaluation of the 2014 Post market review of PBS medicines used to treat asthma in children. |